Wen-Jen Hwu - Researcher Profile | RDL Research Database

Publications

3 shown

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer , Scott S. Tykodi , Laura Q.M. Chow +23 more

Antibody-mediated blockade of PD-L1 induced durable tumor regression (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks...

2012 New England Journal of Medicine 7854 citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid , Caroline Robert , Adil Daud +23 more

In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rat...

2013 New England Journal of Medicine 3352 citations

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert , Antoni Ribas , Jedd D. Wolchok +22 more

2014 The Lancet 1743 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 12,949
Institution: The University of Texas MD Anderson Cancer Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-1674-0751

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.